Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

Cheng, Qinzhen; Kang, Yong; Yao, Bin; Dong, Jinrui; Zhu, Ying; He, Yiling; Ji, Xiaoyuan

doi:10.1002/advs.202302131

Cited by 20 publications

(8 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inspired by living cell drug delivery, researchers have developed a CM-based biomimetic nano-delivery system to improve the oncology therapeutic effects of nanomedicines. These systems show excellent potential for cancer treatment applications including chemotherapy, immunotherapy, phototherapy, and in vivo imaging [ 144 , 145 ]. Different cells perform different tasks in the life activities of the organism and have many unique capabilities.…”

Section: Discussionmentioning

confidence: 99%

Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy

Xia,

Mu,

Yuan

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Nano-delivery systems have demonstrated great promise in the therapy of cancer. However, the therapeutic efficacy of conventional nanomedicines is hindered by the clearance of the blood circulation system and the physiological barriers surrounding the tumor. Inspired by the unique capabilities of cells within the body, such as immune evasion, prolonged circulation, and tumor-targeting, there has been a growing interest in developing cell membrane biomimetic nanomedicine delivery systems. Cell membrane modification on nanoparticle surfaces can prolong circulation time, activate tumor-targeting, and ultimately improve the efficacy of cancer treatment. It shows excellent development potential. This review will focus on the advancements in various cell membrane nano-drug delivery systems for cancer therapy and the obstacles encountered during clinical implementation. It is hoped that such discussions will inspire the development of cell membrane biomimetic nanomedical systems.

show abstract

Section: Discussionmentioning

confidence: 99%

Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy

Xia,

Mu,

Yuan

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…This lack of precision at the molecular level means that the ensuing chemical reactions may occur indiscriminately. Given the functional specificity of proteins and polysaccharides integral to the cell membrane architecture, such nonspecific modifications harbor the potential risk of impairing their intrinsic functionality, thus undercutting the biological efficacy of the modified membranes [ 48 ].…”

Section: Strategies For Engineered Cell Membranesmentioning

confidence: 99%

Engineered Cell Membrane-Camouflaged Nanomaterials for Biomedical Applications

Guan,

Xing,

Liu

2024

Nanomaterials

View full text Add to dashboard Cite

Recent strides in nanomaterials science have paved the way for the creation of reliable, effective, highly accurate, and user-friendly biomedical systems. Pioneering the integration of natural cell membranes into sophisticated nanocarrier architectures, cell membrane camouflage has emerged as a transformative approach for regulated drug delivery, offering the benefits of minimal immunogenicity coupled with active targeting capabilities. Nevertheless, the utility of nanomaterials with such camouflage is curtailed by challenges like suboptimal targeting precision and lackluster therapeutic efficacy. Tailored cell membrane engineering stands at the forefront of biomedicine, equipping nanoplatforms with the capacity to conduct more complex operations. This review commences with an examination of prevailing methodologies in cell membrane engineering, spotlighting strategies such as direct chemical modification, lipid insertion, membrane hybridization, metabolic glycan labeling, and genetic engineering. Following this, an evaluation of the unique attributes of various nanomaterials is presented, delivering an in-depth scrutiny of the substantial advancements and applications driven by cutting-edge engineered cell membrane camouflage. The discourse culminates by recapitulating the salient influence of engineered cell membrane camouflage within nanomaterial applications and prognosticates its seminal role in transformative healthcare technologies. It is envisaged that the insights offered herein will catalyze novel avenues for the innovation and refinement of engineered cell membrane camouflaged nanotechnologies.

show abstract

“…Compared to other nanodrug delivery carriers such as liposomes, polymer nanoparticles, metal nanoparticles, and carbon nanomaterials, CVs have unique superiority as a new type of drug delivery system. CVs have low immunogenicity as they originate from the organism itself, which can prevent premature reductive elimination from the body [ 18 ]. At the same time, CVs have the ability to cross biological barriers, good biocompatibility, capacity for long-distance transport, high drug loading capacity, and effective accumulation at tumor sites, making them a promising nanocarrier for drug delivery [ 19 ].…”

Section: Introductionmentioning

confidence: 99%

Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy

Guo,

Wu,

Chen

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Androgen deprivation therapy (ADT) is a crucial and effective strategy for prostate cancer, while systemic administration may cause profound side effects on normal tissues. More importantly, the ADT can easily lead to resistance by involving the activation of NF-κB signaling pathway and high infiltration of M2 macrophages in tumor microenvironment (TME). Herein, we developed a biomimetic nanotherapeutic platform by deriving cell membrane nanovesicles from cancer cells and probiotics to yield the hybrid cellular nanovesicles (hNVs), loading flutamide (Flu) into the resulting hNVs, and finally modifying the hNVs@Flu with Epigallocatechin-3-gallate (EGCG). In this nanotherapeutic platform, the hNVs significantly improved the accumulation of hNVs@Flu-EGCG in tumor sites and reprogramed immunosuppressive M2 macrophages into antitumorigenic M1 macrophages, the Flu acted on androgen receptors and inhibited tumor proliferation, and the EGCG promoted apoptosis of prostate cancer cells by inhibiting the NF-κB pathway, thus synergistically stimulating the antitumor immunity and reducing the side effects and resistance of ADT. In a prostate cancer mouse model, the hNVs@Flu-EGCG significantly extended the lifespan of mice with tumors and led to an 81.78% reduction in tumor growth compared with the untreated group. Overall, the hNVs@Flu-EGCG are safe, modifiable, and effective, thus offering a promising platform for effective therapeutics of prostate cancer. Graphical Abstract

show abstract

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

Cited by 20 publications

References 159 publications

Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy

Cell Membrane Biomimetic Nano-Delivery Systems for Cancer Therapy

Engineered Cell Membrane-Camouflaged Nanomaterials for Biomedical Applications

Tea polyphenol-engineered hybrid cellular nanovesicles for cancer immunotherapy and androgen deprivation therapy

Contact Info

Product

Resources

About